The goal of this study is to demonstrate that Photon Counting CT (PC-CT) creates similar or better-quality pictures of the body compared to CT systems we currently use in the clinic. The department of Radiology will be conducting this study using the new PC-CT system at MUSC for imaging of the head, neck, and blood vessels. Participants in this study will receive their normally ordered imaging scan as well as an additional imaging scan on the PC-CT machine. This second scan will take place within a month following the first normally ordered imaging study. This additional scan will be the only extra visit for this research study. Risks are the same as a typical CT scan which can include radiation dose, IV dye allergies, risks from IV, and potential loss of confidentiality.

This is a study to determine effectiveness of using catheter directed therapy along with medical directed therapy when treating pulmonary embolism versus using medical directed therapy alone.

This is a Phase I (determine the safety of a drug) study that is looking at how long the contrast agent gadoquatrane stays in the plasma (part of blood not including red cells) after a single injection during an MRI in children aged 0-18 years. Gadoquatrane is an investigational drug, which means that it is not approved by the FDA. This study will be assessing the safety of gadoquatrane for up to 8 days following the administration of gadoquatrane at the MRI. Blood samples will be collected three times within the 8 hours following the MRI for analysis of how much gadoquatrane is left in the blood.

The goal of this study is to help compare scans from the new photon counting CT scanner of a solid lung tumor with traditional lab and biopsy results. Subjects enrolled in this study will receive their normal CT scan on the new photon counting CT scanner that has the capacity to provide pictures that are better quality. These images will provide useful information that may lead to future improvements for patients with similar conditions.